What is COPD?
Chronic obstructive pulmonary disease (COPD) is the medical term used to describe a lung condition that causes the airways to narrow and become obstructed which in turn makes breathing difficult.[1]
When the term is broken down, you can see how the definition gets its meaning:
Chronic: a long-term and ongoing condition that won’t go away
Obstructive: the airways in your lungs have narrowed and become obstructed or blocked, making it difficult for them to move air out
Pulmonary: a condition that affects your lungs
Disease: a recognized medical condition
COPD can be described as a disease of the airways (chronic bronchitis) and/or a disease of the air sacs (emphysema).
- Chronic bronchitis is diagnosed when someone has symptoms of cough for a long time (many months or years) and coughs up phlegm, which is also called sputum or mucus. It is most often caused by smoking, but people who have never smoked who also work or live in places where they breathe dust, biomass fuels (e.g., firewood), chemical fumes, or domestic heating and cooking can also have chronic bronchitis. Gastroesophageal reflux disease (commonly called GERD) is also associated with this diagnosis.
Chronic bronchitis is a result of irritation and inflammation of the bronchial tubes (airways) – the tubes responsible for carrying air through the lungs. The tubes swell and produce a build-up of mucus along the lining. Tiny hair-like structures in the tubes called cilia normally help move the mucus out of the airways, but sometimes they don’t work well. This causes build-up of mucus plugs that are hard to cough up and sometimes make it harder to get air in and out of the lungs. People with chronic bronchitis can also have symptoms of chest or abdominal pain.
- Emphysema is only diagnosed by lung imaging tests (like a CT scan) that show damage to the walls of the tiny air sacs in the lung at the end of the bronchial tubes – called alveoli – this damage makes them enlarged. The alveoli normally play a key role in transferring oxygen into your blood and filtering carbon dioxide back out. Emphysema develops over time, and not everyone with early emphysema has symptoms, but having emphysema can make it difficult to breathe because the enlarged air sacs trap air in the lung. Air trapping is diagnosed using lung function tests.
Approximately 380 million people worldwide are affected by COPD. It is the third leading cause of death behind heart disease and stroke.[2]
If you have chronic obstructive pulmonary disease, it gradually becomes harder to breathe. COPD is progressive, meaning the damage to your lungs can’t be reversed and may progress. Treatment, medication, and lifestyle adjustments can help you learn to manage it more effectively, control your symptoms, and may slow down the progression of COPD.
Helpful Resources
- Patient Empowerment Guides
- Patient Empowerment Scientific Evidence
- Speak-up for COPD
- Asthma + Lung UK
- COPD Foundation
- European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)
- International Primary Care Respiratory Group (IPCRG)
- Longfonds
References
1. GOLD. Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report. GOLD webpage. Published November 2023. Accessed November 28, 2023. https://goldcopd.org/2024-gold-report/
2. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447-458. doi:10.1016/S2213-2600(21)00511-7
3. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921-972. doi:10.1016/S0140-6736(22)01273-9
4. GOLD. Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report. GOLD webpage. Published November 2023. Accessed November 28, 2023. https://goldcopd.org/2024-gold-report/
5. Syamlal G, Kurth LM, Dodd KE, Blackley DJ, Hall NB, Mazurek JM. Chronic Obstructive Pulmonary Disease Mortality by Industry and Occupation — United States, 2020. MMWR Morb Mortal Wkly Rep 2022; 71:1550–1554. DOI: http://dx.doi.org/10.15585/mmwr.mm7149a3.
6. NHS. Chronic Obstructive Pulmonary Disease (COPD) Causes. NHS Website. Updated April 11, 2023. Accessed November 8, 2023. https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/causes/
7. Ramírez-Venegas A, Velázquez-Uncal M, Aranda-Chávez A, Guzmán-Bouilloud NE, Mayar-Maya ME, Pérez Lara-Albisua JL, Hernández-Zenteno RJ, Flores-Trujillo F, Sansores RH. Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial. Int J Chron Obstruct Pulmon Dis. 2019 Aug 6;14:1753-1762. doi: 10.2147/COPD.S201314.
8. Brantly M, Campos M, Davis AM, et al. Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet J Rare Dis. 2020;15(1):96. Published 2020 Apr 19. doi:10.1186/s13023-020-01352-5
9. Alpha-1 Foundation. What is Alpha-1? Alpha-1 Foundation website. Accessed 8 November 2023. https://alpha1.org/what-is-alpha1/
10. Stockley JA, Stockley RA, Sapey E. There is no fast track to identify fast decliners in Alpha-1 antitrypsin deficiency by spirometry: a longitudinal study of repeated measurements. Int J Chron Obstruct Pulmon Dis. 2021;16:835–840. doi:10.2147/COPD.S298585
11. Franciosi AN, Alkhunaizi MA, Woodsmith A, Aldaihani L, Alkandari H, Lee SE, Fee LT, McElvaney NG, Carroll TP. Alpha-1 Antitrypsin Deficiency and Tobacco Smoking: Exploring Risk Factors and Smoking Cessation in a Registry Population. COPD. 2021 Feb;18(1):76-82. doi: 10.1080/15412555.2020.1864725. Epub 2021 Feb 9.
12. Rabe KF, Rennard S, Martinez FJ, et al. Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. Am J Respir Crit Care Med. 2023;208(4):395-405. doi:10.1164/rccm.202303-0455CI
13. GOLD. Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report. GOLD webpage. Published November 2023. Accessed November 28, 2023. https://goldcopd.org/2024-gold-report/
14. Tarín-Carrasco P, Im U, Geels C, Palacios-Peña L, Jiménez-Guerrero P. Contribution of fine particulate matter to present and future premature mortality over Europe: A non-linear response. Environ Int. 2021;153:106517. doi:10.1016/j.envint.2021.106517
15. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921-972. doi:10.1016/S0140-6736(22)01273-9
16. Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019;15(1):24-35. doi:10.1183/20734735.0346-2018
17. Lindenauer PK, Stefan MS, Pekow PS, et al. Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. JAMA. 2020;323(18):1813-1823. doi:10.1001/jama.2020.4437
18. Bogachkov, YY. Pulmonary Rehabilitation Eases Symptoms, Improves Quality of Life. COPD News Today. Published 3 March 2022. Accessed 8 November 2023. https://copdnewstoday.com/news/pulmonary-rehabilitation-eases-copd-symptoms-improves-life-quality/
19. Yun R, Bai Y, Lu Y, Wu X, Lee SD. How Breathing Exercises Influence on Respiratory Muscles and Quality of Life among Patients with COPD? A Systematic Review and Meta-Analysis. Can Respir J. 2021 Jan 29;2021:1904231. doi: 10.1155/2021/1904231.
This page was reviewed by GAAPP clinical and scientific experts in January 2024